Viveve Medical VIVE shares are trading lower after the company said its LIBERATE-International trial in SUI patients did not not achieve its primary endpoint.
“We are very disappointed that the LIBERATE-International trial did not achieve its primary endpoint,” said CEO Scott Durbin. “We have conducted a full review of the primary efficacy data and expect to receive the complete data results including all secondary end-points in early August.”
Mizuho has also downgraded Viveve Medical from Buy to Underperform and lowered the price target from $4 to $0.20.
Viveve Medical shares were trading down 63.55% at 15 cents in Tuesday's pre-market session. The stock has a 52-week high of $3.71 and a 52-week low of 35 cents.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.